Priavoid’s PRI-002 missed its Phase 2 primary efficacy endpoint in Alzheimer’s disease, despite an exploratory 35.9% cognitive signal at Week 72.
Written By: Kirti Kumbhar, PharmD
Reviewed By: Pharmacally Editorial Team
Priavoid GmbH’s oral all-D-peptide candidate PRI-002 (also known as Contraloid acetate or RD2) demonstrated a favorable safety and tolerability profile in the Phase 2 PRImus-AD trial in early Alzheimer’s disease (AD), but failed to meet its primary efficacy endpoint at Week 48. Exploratory Week 72 analyses showed a statistically significant signal in ADAS-Cog13 in the per-protocol population, indicating potential cognitive benefit that requires confirmation.
Phase 2 PRImus-AD results show mixed efficacy outcomes
The randomized, double-blind, placebo-controlled Phase 2 PRImus-AD trial (NCT06182085) evaluated PRI-002 in 304 patients aged 55–80 years with mild cognitive impairment (MCI) or mild dementia due to AD. Conducted across 38 clinical sites in six European countries, the study randomized participants 1:1:1 to receive oral PRI-002 at 300 mg daily, 600 mg daily or placebo.
The common-close design allowed treatment durations ranging from 48 to 96 weeks. The study concluded when the last enrolled participant completed 48 weeks of treatment, allowing earlier-enrolled participants to receive longer exposure. Efficacy analyses included modified intention-to-treat (mITT) and per-protocol populations. The two PRI-002 dose groups were pooled for efficacy analyses because their plasma concentrations substantially overlapped.
The primary efficacy endpoint was change from baseline in Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 48. Secondary assessments included cognition measured by Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog13), daily functioning assessed by Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL), and additional cognitive measures.
Primary Efficacy Endpoint: CDR-SB
PRImus-AD did not meet its primary CDR-SB efficacy endpoint at Week 48. The company did not disclose the corresponding percentage slowing or p-values for the mITT and per-protocol populations in its topline announcement. At Week 72, exploratory analyses showed 12% slowing of decline in the mITT population (p=0.459) and 18.8% in the per-protocol population (p=0.266). Neither result reached statistical significance.
ADAS-Cog13: Cognitive Outcomes
On ADAS-Cog13, PRI-002 was associated with 19.0% slowing of cognitive decline in the mITT population (p=0.491) and 23.3% in the per-protocol population (p=0.383) at Week 48. At Week 72, the corresponding differences increased to 26.7% (p=0.102) and 35.9% (p=0.022), respectively. The per-protocol result reached statistical significance, although the mITT finding remained nonsignificant.
ADCS-ADL: Daily Functioning
ADCS-ADL showed numerical differences favoring PRI-002 at both assessment points. At Week 48, the differences were 7.5% in the mITT population (p=0.775) and 16.9% in the per-protocol population (p=0.507). At Week 72, these increased to 27.1% (p=0.120) and 30.4% (p=0.080), respectively. None reached statistical significance.
These percentage differences represent reported slowing of decline or differences favoring treatment, rather than absolute improvements in clinical scores. The Week 72 findings are exploratory and should be interpreted in the context of the smaller population available for extended follow-up under the common-close design.
Safety and Tolerability
PRI-002 met its primary safety endpoint, with the company reporting a favorable overall safety and tolerability profile. At Week 48, treatment-emergent adverse events (TEAEs) occurred in 80.0% of patients receiving 300 mg, 71.8% receiving 600 mg and 77.0% receiving placebo. Serious TEAEs were reported in 9.0%, 8.7% and 8.0%, respectively. Adverse events leading to discontinuation, interruption or dose adjustment occurred in 3.9%, 13.0% and 13.0%, respectively. Commonly reported events included headache, nausea and dizziness.
By the end of the study, investigator-reported amyloid-related imaging abnormalities included ARIA-E (edema) in 2% of patients receiving 300 mg, 0% receiving 600 mg and 1% receiving placebo. ARIA-H (hemorrhage) occurred in 8%, 11.7% and 5%, respectively. Although ARIA-E incidence remained low, ARIA-H was numerically higher in both active treatment groups. The clinical significance requires further assessment. An unblinded Data Safety Monitoring Board recommended discontinuing close ARIA monitoring through centralized MRI reading after the first 90 patients completed 24 weeks of treatment.
Preliminary Biomarker Findings and Mechanism
Preliminary biomarker observations included cerebrospinal fluid (CSF) phosphorylated tau 181 (p-tau181). Priavoid described an increasing change relative to placebo beginning at 24 weeks, but the topline announcement did not provide the direction, magnitude or statistical significance of this difference. Further analyses of Alzheimer’s disease-related biomarkers and brain volumetric measurements are ongoing. These findings cannot yet establish disease modification.
PRI-002 is an orally available all-D-peptide candidate developed using Priavoid’s proprietary detangler platform. It is designed to bind neurotoxic amyloid-beta (Aβ) oligomers and promote their disassembly into non-toxic monomers. Unlike monoclonal antibody approaches that use Fc-mediated immune effector mechanisms, PRI-002 is designed to target oligomer-associated neurotoxicity directly without relying on antibody-mediated amyloid clearance. This mechanistic distinction does not establish the absence of treatment-associated ARIA or other safety risks.
Clinical Interpretation and Development Outlook
PRImus-AD presents a mixed Phase 2 outcome: PRI-002 met its primary safety endpoint but failed to demonstrate efficacy on the primary CDR-SB endpoint at Week 48. The 35.9% slowing of cognitive decline on ADAS-Cog13 at Week 72 in the per-protocol population provides an exploratory efficacy signal. However, its absence in the mITT analysis and the lack of statistically significant findings across CDR-SB and ADCS-ADL limit the overall clinical interpretation.
Priavoid is conducting further analyses of the trial dataset, with the full results expected at scientific conferences in 2027. These findings will inform subsequent development decisions, including the potential design of another clinical study. PRI-002 remains investigational, and its Phase 2 findings do not establish clinical efficacy or disease-modifying benefit.
Reference
Priavoid Announces Topline Phase 2 Data for Oral All-D-Peptide PRI-002 in Alzheimer’s Disease at CTAD 2026, Priavoid, 17 November 2026
Study to Assess Safety and Efficacy of PRI-002 in Patients with MCI to Mild Dementia Due to Alzheimer’s Disease (AD) (PRImus-AD), ClinicalTrials.gov ID NCT06182085
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.
